Business context and reporting period
Spyre Therapeutics, Inc. reported on October 5, 2026, that it entered into an underwriting agreement for a public offering of common stock. The offering was expected to close on or about October 7, 2026, subject to customary closing conditions.
Offering and key financial terms
- Base offering: 4,117,648 shares at $85.00 per share.
- Expected gross proceeds: approximately $350.0 million, before underwriting discounts, commissions, and estimated offering expenses.
- Underwriters received a 30-day option to buy up to 617,647 additional shares on the same terms. Proceeds from any option shares are not included in the stated base offering amount.
- The filing does not provide a clear value for net proceeds, and does not report revenue, profit, cash flow, margins, debt, or liquidity metrics.
Use of proceeds and outlook
Spyre plans to use net proceeds to advance its Gastroenterology, Rheumatology, and Dermatology programs, including preclinical studies, clinical trials, manufacturing, and Phase 3 readiness. It also expects to support late-stage development of SPY072 for hidradenitis suppurativa, general infrastructure, and potentially acquisitions, in-licensing, or investments. Remaining proceeds may support ongoing research and development, working capital, and general corporate purposes.
Changes, risks, and other considerations
This filing describes an equity financing, not operating results; it provides no comparable-period financial information. Issuing the shares will increase the number of shares outstanding, but the filing does not provide enough information to quantify the resulting dilution. The offering remains subject to closing conditions. The underwriting agreement includes customary representations, indemnification provisions, and termination rights.
Important facts to verify
- Whether the offering closed as expected and whether the underwriters exercised their option.
- Final net proceeds after discounts, commissions, and expenses.
- Updated share count and dilution following the offering.
- Progress and funding allocation across Spyre’s programs, including SPY072.